NCT04888312 - Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2021

Primary Completion Date

June 1, 2026

Study Completion Date

June 30, 2026

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

BIOLOGICAL

CD40 agonist mitazalimab in combination with chemotherapy

Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.

Trial Locations (14)

Universitair Ziekenhuis Gent, Ghent

Hopital Européen Georges Pompidou, Paris

Cliniques Universitaires St-Luc, Brussels

Hospital Erasme, Brussels

UZA Antwerp, Edegem

Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque,, Bordeaux

Centre Lyon Berard, Lyon

Institut Paoli-Calmettes, Marseille

Institute de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona

Hospital Universitario La Paz, Madrid, Spain, Madrid

Hospital Universitario Ramon y Cajal, Madrid, Spain, Madrid

Hospital Universitario Virgen del Rocio, Sevilla, Spain, Seville

Hospital Universitario Miguel Servet, Zaragoza, Spain, Zaragoza